The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumors: a review Abraham GoldinJohn M. VendittiRuth Geran Preclinical Review Pages: 3 - 21
Additive cytotoxicity of adriamycin and a naturally occurring growth inhibitor extracted from bovine aorta Max HaidJustin CohenJeanne D. Travis Preclinical Studies Pages: 23 - 29
Effect of inhibition of γ-glutamyltranspeptidase by AT-125 (Acivicin) on glutathione and cysteine levels in rat brain and plasma Kristina E. HillDaniel D. Von HoffRaymond F. Burk Preclinical Studies Pages: 31 - 34
Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor Daniel S. ZaharkoJoseph M. CoveyJames A. Kelley Pharmacology Studies Pages: 35 - 41
Stability of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ; NSC 224070) in aqueous solutions by high-performance liquid chromatography Andrew G. BosanquetSheila B. McLoughlin Pharmacology Studies Pages: 43 - 50
Radioimmunoassay for mitoxantrone, a new antitumor agent G. NicolauV. Szucs-MyersA. Lanzilotti Pharmacology Studies Pages: 51 - 56
Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule William J. MoriconiSarah TaylorBarth Hoogstraten Clinical Trials Pages: 57 - 62
Epirubicin in colorectal cancer Eduard E. HoldenerHeine H. HansenMarcel Rozencweig Clinical Trials Pages: 63 - 66
Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma Sarah A. TaylorBill T. TranumJohn J. Costanzi Clinical Trials Pages: 67 - 69
Trimetrexate: a new antifol entering clinical trials Peter J. O'DwyerD. Dale ShoemakerB. Leyland-Jones Clinical Trials Pages: 71 - 75